Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.75
Bid: 42.00
Ask: 43.50
Change: -2.60 (-6.05%)
Spread: 1.50 (3.571%)
Open: 42.75
High: 40.40
Low: 40.40
Prev. Close: 43.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

4 Jan 2011 18:28

Avacta Group plc ("Avacta" or "the Company") Holdings in Company

The Company was notified on 31 December 2010 that IP Group Plc ("IP Group"), a substantial shareholder of the Company, had purchased 1,375,000 ordinary shares of 0.1p each in Avacta ("Ordinary Shares") at £0.0086 per share on 29 December 2010.

IP Group then purchased an additional 2,000,000 Ordinary Shares on 31 December 2010 at £0.0093 per share.

Alan Aubrey is a Non-Executive Director of the Company and the CEO of IP Group. As a result of these transactions, his direct holding in the issued share capital of the Company has remained unchanged but his indirect holding has increased from 0.108% to 0.109%.

IP Group now has a beneficial interest in 363,995,694 Ordinary Shares in the Company, representing 25.34% of the issued share capital.

Enquiries:

Avacta Group plc Tel: 0844 414 0452 Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer Broker - XCAP Securities Plc Tel: 020 7101 7070 John Grant/Karen Kelly/David Newton NOMAD - Grant Thornton Corporate Finance Tel: 020 7383 5100 Philip Secrett/Colin Aaronson/David Hignell PR - NexFin Nicholas Nelson Tel: 07921 522 920 nicholas.nelson@nexfin.co

The Company's website is www.avacta.com

vendor
Date   Source Headline
10th Oct 20177:00 amRNSAvacta to Present at Major US Conference
9th Oct 20174:02 pmRNSDirector Dealing and Issue of Equity
5th Oct 20177:00 amRNSResearch collaboration with FIT Biotech Oy
4th Oct 20177:00 amRNSPreliminary Results
2nd Oct 20177:00 amRNSAvacta establishes US business development team
7th Sep 20177:00 amRNSNotice of Results
21st Aug 201712:00 pmRNSDirector/PDMR Shareholding
7th Aug 20177:00 amRNSTrading Update
31st Jul 201712:00 pmRNSIssue of Equity
28th Jul 20171:15 pmRNSDirector/PDMR Shareholding
5th Jul 20177:00 amRNSDirector Dealing and Issue of Equity
4th Jul 20177:00 amRNSManchester ShareSoc Growth Company Seminar
5th Jun 20177:00 amRNSShareSoc Growth Company Seminar
1st Jun 20178:56 amRNSIssue of Equity
22nd May 20177:00 amRNS2 Biotech's Licence Affimers for Research Use
10th May 20177:00 amRNSKey Affimer Patent To Be Granted in China
8th May 20171:21 pmRNSHardman Research: De-risking Moderna's partnership
5th May 20177:00 amRNSPresenting at the Hardman Private Investor Forum
2nd May 20177:00 amRNSAvacta to Present at BioTrinity 2017
24th Apr 20177:00 amRNSDiagnostics firm take rights to several Affimers
19th Apr 20177:00 amRNSAvacta to Present at the Shares Spotlight Evening
12th Apr 20177:15 amRNSHardman Research: Another important box ticked
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 20172:23 pmRNSHolding(s) in Company
6th Apr 201710:22 amRNSDirector/PDMR Shareholding
3rd Apr 20177:00 amRNSInterim Results for the Period Ended 31 Jan 2017
3rd Apr 20177:00 amRNSResults of Immunogenicity Study with Human Samples
31st Mar 20179:31 amRNSAvacta Presents at Investor Evening Hosted by TPI
31st Mar 20177:00 amRNSLondon Growth and Innovation Forum Presentation
22nd Mar 20179:00 amRNSAvacta to present at the UK Investor Show
21st Mar 20177:15 amRNSHardman Research: Low response would be positive!
30th Jan 20177:00 amRNSDirector/PDMR Shareholding
20th Jan 201711:35 amRNSResult of Annual General Meeting
20th Jan 20177:00 amRNSTrading Update
11th Jan 20177:00 amRNSPresenting at London Growth and Innovation Forum
5th Jan 20177:00 amRNSDirector Dealing and Issue of Equity
20th Dec 20167:00 amRNSDirector/PDMR Shareholding
16th Dec 20165:14 pmRNSHolding(s) in Company
1st Dec 20167:00 amRNSNotice of AGM, Accounts and Directorate Change
23rd Nov 20167:00 amRNSTechnical Update: Affinity Separation
7th Nov 20167:00 amRNSCancer Expert joins Scientific Advisory Board
2nd Nov 20167:00 amRNSCAR-T Cell Therapy Research Collaboration in US
1st Nov 20167:00 amRNSResults from first Affimer pre-clinical studies
21st Oct 201611:39 amRNSDirector's Dealing
17th Oct 20161:00 pmRNSHardman Research: Great strides to strategic goals
17th Oct 20167:00 amRNSPrelim Results for the Year Ended 31 July 2016
4th Oct 20163:28 pmRNSIssue of Equity
26th Sep 201611:21 amRNSNotice of Results
22nd Sep 20167:00 amRNSPositive results from first preclinical studies
12th Sep 20167:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.